drugset / Trial / NCT02009631

A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors

NCT02009631

Phase 1 Completed 45 enrolled AbbVie
RandomizedCrossoverQuadruple-blindOther

Summary

This is a randomized Phase 1 study to evaluate the effects of Veliparib on cardiac repolarization in patients with solid tumors who's cancer has recurred or is no longer responding to current treatment.

Timeline

Start
2013-11
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Veliparib Small molecule 200 mg Oral
Subject Veliparib Small molecule 400 mg Oral